Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma
Sponsor: Abramson Cancer Center at Penn Medicine
Listed as NCT00568880, this PHASE1 trial focuses on Multiple Myeloma and Plasma Cell Neoplasm and remains completed. Sponsored by Abramson Cancer Center at Penn Medicine, it has been updated 9 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — May 2023 [monthly]
Completed PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1
Phase: PHASE1_PHASE2 → PHASE1
▶ Show 4 earlier versions
-
May 2019 — Mar 2020 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — May 2019 [monthly]
Unknown Status PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abramson Cancer Center at Penn Medicine
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Philadelphia, United States